Cleveland Clinic physicians assessed fertility-sparing procedures for patients with early-stage cervical cancer.
Fertility preservation is currently not an option for prepubescent males who are undergoing gonadotoxic treatment or who have an infertility-causing disease, as they are unable to provide a semen sample. A team of Cleveland Clinic urologists and pediatric oncologists is hoping to change this.
Access to fertility preservation programs for pediatric cancer patients is becoming increasingly important; however, the barriers to access these services are cause for concern.
Patients with early cervical cancer have an excellent prognosis and about 40% of them are of reproductive age, making fertility a key concern for them. This article explores the oncologic and reproductive outcomes of fertility sparing procedures for this patient population.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
Many women receiving chemotherapy face the prospect of premature menopause because the drugs destroy ovarian follicles. New research is helping to unlock the keys to use of AMHR2BP, a peptide that mimics anti-Müllerian hormone, to preserve fertility in these patients.
Many factors determine the best fertility or hormonal preservation option for each patient. In this article, fertility specialist Laura Detti, MD, and gynecologic oncologist Robert DeBernardo, MD, discuss their approach to fertility preservation for women facing surgery for endometriosis or gynecologic cancer.
Although cancer can damage the ovaries, leading to infertility and early menopause, young women with cancer have several options for fertility preservation. Gynecologic oncologist Mariam AlHilli, MD, discusses a case in which three different fertility preservation procedures were conducted to give a young woman her best chance at future fertility.
With advances in pediatric cancer treatment routinely enabling long-term survival, counseling young patients and their families before treatment about infertility risk and preservation strategies is essential.
Women with cancer have options for fertility preservation – from the gold standard of egg and embryo freezing to ovarian tissue vitrification and ovary-protecting hormone injections – yet most don’t pursue.
When is a patient a candidate for pregnancy with potential for a good outcome? When is pregnancy out of the question? How to answer these questions and more for women after cancer treatment.